These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2576163)

  • 1. Current studies related to the development of transmission-blocking malaria vaccines: a review.
    Meuwissen JH
    Trans R Soc Trop Med Hyg; 1989; 83 Suppl():57-60. PubMed ID: 2576163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward the development of effective transmission-blocking vaccines for malaria.
    Nikolaeva D; Draper SJ; Biswas S
    Expert Rev Vaccines; 2015 May; 14(5):653-80. PubMed ID: 25597923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malaria transmission-enhancing activity in mosquitoes by mammalian host anti-sporozoite antibodies.
    Hollingdale MR; do Rosario V
    Exp Parasitol; 1989 Apr; 68(3):365-8. PubMed ID: 2564825
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of malaria vaccines that block transmission of parasites by mosquito vectors.
    Hisaeda H; Yasutomo K
    J Med Invest; 2002 Aug; 49(3-4):118-23. PubMed ID: 12323000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy model for mosquito stage transmission blocking vaccines for malaria.
    Saul A
    Parasitology; 2008 Nov; 135(13):1497-506. PubMed ID: 18257944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 'do unto others' malaria vaccine.
    Vogel G
    Science; 2010 May; 328(5980):847-8. PubMed ID: 20466919
    [No Abstract]   [Full Text] [Related]  

  • 7. Mosquito-based transmission blocking vaccines for interrupting Plasmodium development.
    Lavazec C; Bourgouin C
    Microbes Infect; 2008 Jul; 10(8):845-9. PubMed ID: 18656409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies.
    Quakyi IA; Carter R; Rener J; Kumar N; Good MF; Miller LH
    J Immunol; 1987 Dec; 139(12):4213-7. PubMed ID: 2447164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mosquito stage, transmission blocking vaccines for malaria.
    Saul A
    Curr Opin Infect Dis; 2007 Oct; 20(5):476-81. PubMed ID: 17762780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission-blocking vaccines: uses and current status of development.
    Kaslow DC
    Int J Parasitol; 1997 Feb; 27(2):183-9. PubMed ID: 9088989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-Faced Immunity? The Evidence for Antibody Enhancement of Malaria Transmission.
    Stone W; Bousema T; Sauerwein R; Drakeley C
    Trends Parasitol; 2019 Feb; 35(2):140-153. PubMed ID: 30573175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission immunity in malaria: reflections on the underlying immune mechanisms during natural infections and following artificial immunization.
    Carter R; Mendis K
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():169-73. PubMed ID: 1364201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimalarial transmission-blocking vaccines.
    Sinden RE
    Sci Prog; 1993-1994; 77 ( Pt 1-2)():1-14. PubMed ID: 7801089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission blocking malaria vaccines: Assays and candidates in clinical development.
    Sauerwein RW; Bousema T
    Vaccine; 2015 Dec; 33(52):7476-82. PubMed ID: 26409813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium Oocysts: Overlooked Targets of Mosquito Immunity.
    Smith RC; Barillas-Mury C
    Trends Parasitol; 2016 Dec; 32(12):979-990. PubMed ID: 27639778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria.
    Peiris JS; Premawansa S; Ranawaka MB; Udagama PV; Munasinghe YD; Nanayakkara MV; Gamage CP; Carter R; David PH; Mendis KN
    Am J Trop Med Hyg; 1988 Jul; 39(1):26-32. PubMed ID: 3041855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative assessment of An. gambiae and An. stephensi mosquitoes to determine transmission-reducing activity of antibodies against P. falciparum sexual stage antigens.
    Eldering M; Bompard A; Miura K; Stone W; Morlais I; Cohuet A; van Gemert GJ; Brock PM; Rijpma SR; van de Vegte-Bolmer M; Graumans W; Siebelink-Stoter R; Da DF; Long CA; Morin MJ; Sauerwein RW; Churcher TS; Bousema T
    Parasit Vectors; 2017 Oct; 10(1):489. PubMed ID: 29041962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target antigens in malaria transmission blocking immunity.
    Carter R; Miller LH; Rener J; Kaushal DC; Kumar N; Graves PM; Grotendorst CA; Gwadz RW; French C; Wirth D
    Philos Trans R Soc Lond B Biol Sci; 1984 Nov; 307(1131):201-13. PubMed ID: 6151684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-gamete monoclonal antibodies synergistically block transmission of malaria by preventing fertilization in the mosquito.
    Rener J; Carter R; Rosenberg Y; Miller LH
    Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6797-9. PubMed ID: 6935685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.